Source Name	Characteristics[organism]	Characteristics[organism part]	Characteristics[cell type]	Characteristics[cell line]	Characteristics[developmental stage]	Characteristics[disease]	Characteristics[ancestry category]	Characteristics[sex]	Characteristics[age]	Characteristics[biological replicate]	Characteristics[time]	Characteristics[treatment]	Characteristics[individual]	Material Type	technology type	assay name	comment[data file]	comment[file uri]	comment[technical replicate]	comment[fraction identifier]	comment[label]	comment[instrument]	comment[modification parameters]	comment[modification parameters]	comment[cleavage agent details]	comment[precursor mass tolerance]	comment[fragment mass tolerance]	Factor Value[time]	Factor Value[treatment]
Sample 1	Homo sapiens	breast	not applicable	not applicble	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab+pertuzumab	101	tissue	proteomic profiling by mass spectrometer	run 1	20151118_HER2_01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_01.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab+pertuzumab
Sample 2	Homo sapiens	breast	not applicable	not applicble	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab+pertuzumab	101	tissue	proteomic profiling by mass spectrometer	run 2	20151118_HER2_02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_02.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab+pertuzumab
Sample 3	Homo sapiens	breast	not applicable	not applicble	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab	103	tissue	proteomic profiling by mass spectrometer	run 3	20151118_HER2_03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_03.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab
Sample 4	Homo sapiens	breast	not applicable	not applicble	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab	103	tissue	proteomic profiling by mass spectrometer	run 4	20151118_HER2_04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_04.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab
Sample 5	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab+lapatinib	107	tissue	proteomic profiling by mass spectrometer	run 5	20151118_HER2_06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_06.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab+lapatinib
Sample 6	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab+pertuzumab	109	tissue	proteomic profiling by mass spectrometer	run 6	20151118_HER2_07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_07.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab+pertuzumab
Sample 7	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab+pertuzumab	109	tissue	proteomic profiling by mass spectrometer	run 7	20151118_HER2_08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_08.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab+pertuzumab
Sample 8	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	pertuzumab	111	tissue	proteomic profiling by mass spectrometer	run 8	20151118_HER2_09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_09.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	pertuzumab
Sample 9	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	pertuzumab	111	tissue	proteomic profiling by mass spectrometer	run 9	20151118_HER2_10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_10.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	pertuzumab
Sample 10	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab+lapatinib	107	tissue	proteomic profiling by mass spectrometer	run 10	20151118_HER2_29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_29.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab+lapatinib
Sample 11	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab+lapatinib	112	tissue	proteomic profiling by mass spectrometer	run 11	20151120_HER2_11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151120_HER2_11.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab+lapatinib
Sample 12	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab+lapatinib	112	tissue	proteomic profiling by mass spectrometer	run 12	20151120_HER2_12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151120_HER2_12.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab+lapatinib
Sample 13	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab	113	tissue	proteomic profiling by mass spectrometer	run 13	20151120_HER2_13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151120_HER2_13.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab
Sample 14	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab	113	tissue	proteomic profiling by mass spectrometer	run 14	20151120_HER2_30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151120_HER2_30.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab
Sample 15	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab+pertuzumab	115	tissue	proteomic profiling by mass spectrometer	run 15	20151121_HER2_15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151121_HER2_15.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab+pertuzumab
Sample 16	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab+pertuzumab	115	tissue	proteomic profiling by mass spectrometer	run 16	20151121_HER2_16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151121_HER2_16.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab+pertuzumab
Sample 17	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	pertuzumab	116	tissue	proteomic profiling by mass spectrometer	run 17	20151121_HER2_17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151121_HER2_17.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	pertuzumab
Sample 18	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	pertuzumab	116	tissue	proteomic profiling by mass spectrometer	run 18	20151121_HER2_18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151121_HER2_18.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	pertuzumab
Sample 19	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab	117	tissue	proteomic profiling by mass spectrometer	run 19	20151122_HER2_19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_19.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab
Sample 20	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab	117	tissue	proteomic profiling by mass spectrometer	run 20	20151122_HER2_20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_20.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab
Sample 21	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	pertuzumab	118	tissue	proteomic profiling by mass spectrometer	run 21	20151122_HER2_21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_21.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	pertuzumab
Sample 22	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	pertuzumab	118	tissue	proteomic profiling by mass spectrometer	run 22	20151122_HER2_22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_22.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	pertuzumab
Sample 23	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab+pertuzumab	119	tissue	proteomic profiling by mass spectrometer	run 23	20151122_HER2_23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_23.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab+pertuzumab
Sample 24	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab+pertuzumab	119	tissue	proteomic profiling by mass spectrometer	run 24	20151122_HER2_24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_24.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab+pertuzumab
Sample 25	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab+pertuzumab	120	tissue	proteomic profiling by mass spectrometer	run 25	20151122_HER2_25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_25.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab+pertuzumab
Sample 26	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab+pertuzumab	120	tissue	proteomic profiling by mass spectrometer	run 26	20151122_HER2_26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_26.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab+pertuzumab
Sample 27	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab+lapatinib	121	tissue	proteomic profiling by mass spectrometer	run 27	20151122_HER2_27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_27.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab+lapatinib
Sample 28	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab+lapatinib	121	tissue	proteomic profiling by mass spectrometer	run 28	20151122_HER2_28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_28.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab+lapatinib
Sample 29	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	pertuzumab	111	tissue	proteomic profiling by mass spectrometer	run 29	20151123_HER2_10rerun.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151123_HER2_10rerun.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	pertuzumab
Sample 30	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab	103	tissue	proteomic profiling by mass spectrometer	run 30	20170113_Johnson_103-O.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_103-O.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab
Sample 31	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab	103	tissue	proteomic profiling by mass spectrometer	run 31	20170113_Johnson_103-R.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_103-R.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab
Sample 32	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab	108	tissue	proteomic profiling by mass spectrometer	run 32	20170113_Johnson_108-O.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_108-O.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab
Sample 33	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab	108	tissue	proteomic profiling by mass spectrometer	run 33	20170113_Johnson_108-R.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_108-R.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab
Sample 34	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab	123	tissue	proteomic profiling by mass spectrometer	run 34	20170113_Johnson_123-O.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_123-O.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab
Sample 35	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab	123	tissue	proteomic profiling by mass spectrometer	run 35	20170113_Johnson_123-R.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_123-R.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab
Sample 36	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab+lapatinib	125	tissue	proteomic profiling by mass spectrometer	run 36	20170113_Johnson_125-O.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_125-O.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	trastuzumab+lapatinib
Sample 37	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab+lapatinib	125	tissue	proteomic profiling by mass spectrometer	run 37	20170113_Johnson_125-R.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_125-R.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	trastuzumab+lapatinib
Sample 38	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	pertuzumab	128	tissue	proteomic profiling by mass spectrometer	run 38	20170113_Johnson_128-O.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_128-O.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Post	pertuzumab
Sample 39	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	pertuzumab	128	tissue	proteomic profiling by mass spectrometer	run 39	20170113_Johnson_128-R.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_128-R.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	Pre	pertuzumab
